BioCentury
ARTICLE | Company News

Pharmaxis, Boehringer Ingelheim deal

May 25, 2015 7:00 AM UTC

Boehringer exercised its option to acquire worldwide rights to anti-inflammatory candidate PXS4728A and related molecules from Pharmaxis. Boehringer plans to develop the oral vascular adhesion protein-1 (VAP-1; SSAO) inhibitor to treat nonalcoholic steatohepatitis (NASH). The compound is in a Phase I trial to treat inflammatory disease. ...